Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib-based combination therapy for primary or secondary central nervous system diffuse large B-cell lymphoma
ChiCTR2000039485Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of zanubrutinib in Diffuse Large B-Cell Primary Central Nervous System Lymphoma, primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Head MRI and Cerebrospinal fluid flow cytometry. Started Dec 2020; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphomaprimary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2000039485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039485.